



Dr Sara Trompeter is a Consultant Haematoloaist and Paediatric Haematologist at University College Hospitals London and NHS Blood and Transplant. She graduated from the University of Bristol in 1997 with degrees in Medicine MBChB and Psychology BSc. She was awarded MRCPCH by the Royal College of Paediatrics and Child Health in 1999. FRCPath by the Royal College of Pathology in 2007 and an MSc from the University of Oxford in 2017. She was appointed consultant haematologist at NHS Blood and Transplant and UCLH in 2011. She is the lead for paediatric haematology and a core member of the adult previous chair of service. As the Joint Red Cell Unit Haemoglobinopathy Network including hospitals UCLH, Whittington

Health, Roval Free Hospital, Roval Free Hospital Barnet Branch and Luton and Dunstable Hospital she led the trust through the 2012 Peer Review Process. She has supported and developed the arowth of the automated exchange service at UCLH to be the largest in Europe. She is a Clinical Representative on the NHSE Clinical Reference Group for Haemoalobinopathies and on the interim steering group of the National Haemoglobinopathy Registry.

Dr Trompeter leads the paediatric red cell research programme at UCLH. She is involved in and spearheading much research into the appropriate use of transfusion in red cell disorders. Much of her research interest involves looking at microvesicles and coagulation in sickle cell disease, stem cell generated blood and pathogen inactivated blood as well as novel therapies in haemoglobin disorders. She has lectured and published on many aspects of red cell disorders.

In her role at NHS Blood and Transplant she is developing an evidence base for transfusion in haemoalobinopathies and is involved in various projects including looking at the feasibility of genotyping donors the haemoalobinopathy patient genotyping project where all patients in England were offered free genotyping including CDE variants and was the lead on the National Comparative Audit of Transfusion in sickle cell disease 2014. She supports NHS Blood and Transplant to Identify the current and future transfusion needs of haemoalobinopathy patients provide NHSBT with the best information available on current gaps in provision and future demand and requirements develop audits relating to appropriate blood transfusion for the benefit of haemoalobinopathy patients within NHSBT be informed regarding research developments and secure funding for research and development of transfusion therapy in sickle cell disease and support and liaise with the donor area of NHSBT to inform and encourage donations that may benefit the patient group.